awmsg logo



enzalutamide (Xtandi®)


Reference No. 1773

Publication date:
04/09/2015


Appraisal information

enzalutamide (Xtandi®) 40 mg capsule


Company: Astellas Pharma Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/04/2015
AWMSG meeting date: 15/07/2015
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1415
Ministerial ratification: 01/09/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA377) NICE GUIDANCE ISSUED JANUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Enzalutamide (Xtandi®) is recommended as an option for use within NHS Wales for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download